PharmaEssentia Yönetim

Yönetim kriter kontrolleri 3/4

PharmaEssentia CEO'su Ko-Chung Lin, Jan2017 tarihinde atandı, in görev süresi 7.83 yıldır. şirketin hisselerinin 1.73% doğrudan sahiptir ve bu hisselerin değeri $ 100.33M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 3.3 yıldır.

Anahtar bilgiler

Ko-Chung Lin

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	7.8yrs
CEO sahipliği	1.7%
Yönetim ortalama görev süresi	5.1yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ko-Chung Lin'un ücretlendirmesi PharmaEssentia'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	NT$2b
Jun 30 2024	n/a	n/a	NT$1b
Mar 31 2024	n/a	n/a	NT$442m
Dec 31 2023	n/a	n/a	-NT$624m
Sep 30 2023	n/a	n/a	-NT$890m
Jun 30 2023	n/a	n/a	-NT$1b
Mar 31 2023	n/a	n/a	-NT$2b
Dec 31 2022	n/a	n/a	-NT$1b
Sep 30 2022	n/a	n/a	-NT$2b
Jun 30 2022	n/a	n/a	-NT$2b
Mar 31 2022	n/a	n/a	-NT$3b
Dec 31 2021	NT$9m	NT$9m	-NT$3b
Sep 30 2021	n/a	n/a	-NT$3b
Jun 30 2021	n/a	n/a	-NT$3b
Mar 31 2021	n/a	n/a	-NT$2b
Dec 31 2020	NT$9m	NT$9m	-NT$2b
Sep 30 2020	n/a	n/a	-NT$1b
Jun 30 2020	n/a	n/a	-NT$862m
Mar 31 2020	n/a	n/a	-NT$856m
Dec 31 2019	NT$9m	NT$8m	-NT$843m

Tazminat ve Piyasa: Ko-Chung şirketinin toplam tazminatının Luxembourg pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Ko-Chung 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ko-Chung Lin

7.8yrs

Görev süresi

NT$9,389,000

Tazminat

Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ching-Leou Teng	Chairman & Chief Pharmaceutical Officer	12.2yrs	NT$8.49m	1.09% $ 63.1m
Ko-Chung Lin	Founder	7.8yrs	NT$9.39m	1.73% $ 100.3m
Chan-Kou Hwang	President	no data	NT$8.49m	0.61% $ 35.1m
Snow Chang	Accounting Manager & Senior Manager of Finance	9.1yrs	Veri yok	Veri yok
Samuel Lin	VP and Head of Business Operations & Strategy	2.8yrs	Veri yok	Veri yok
Lih-Ling Lin	Chief Scientific Officer	2.3yrs	Veri yok	0.010% $ 593.8k
Rachel Lipsitz	VP and Head of Corporate Communications & Advocacy	2.8yrs	Veri yok	Veri yok
Roddy Mcilwain	Senior VP and Head of Sales & Marketing	3.8yrs	Veri yok	Veri yok
Anjana Pursnani	Senior VP & Head of People	2.8yrs	Veri yok	Veri yok
Albert Qin	Chief Medical Officer	7.8yrs	Veri yok	0.0061% $ 353.5k
Narihisa Miyachi	Head of Japan Medical Affairs	6.3yrs	Veri yok	Veri yok
Yen-Tung Luan	Chief Operating Officer of Taichung Plant	6.3yrs	Veri yok	Veri yok

5.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 261280558 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ching-Leou Teng	Chairman & Chief Pharmaceutical Officer	12.2yrs	NT$8.49m	1.09% $ 63.1m
Ko-Chung Lin	Founder	3.3yrs	NT$9.39m	1.73% $ 100.3m
Chan-Kou Hwang	President	9.5yrs	NT$8.49m	0.61% $ 35.1m
Jeffrey R. Williams	Independent Director	less than a year	Veri yok	Veri yok
Ching-Tsun Liu	Independent Director	less than a year	Veri yok	0.13% $ 7.4m
Jinn-Der Chang	Independent Director	10.7yrs	NT$120.00k	0.029% $ 1.7m
Jien-Heh Tien	Independent Director	6.4yrs	NT$120.00k	0.00060% $ 34.8k
Ming-Chuan Hsieh	Independent Director	less than a year	Veri yok	0.0012% $ 69.6k
Norio Komatsu	Chairperson of Japan	3.5yrs	Veri yok	Veri yok
Shen Yi Li	Director	3.3yrs	NT$95.00k	0.24% $ 14.2m
HsuehFang Hsu	Director	less than a year	Veri yok	Veri yok
ChenJung Hsiao	Director	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 261280558 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

PharmaEssentia Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pharmaessentia Corporation Announces Appointments to Board of Directors

Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

Recent updates

PharmaEssentia Corporation to Report Q3, 2024 Results on Nov 14, 2024

PharmaEssentia Corporation Announces Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon Alfa-2b for Essential Thrombocythemia (ET)

PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle

PharmaEssentia Corporation to Report Q2, 2024 Results on Aug 13, 2024

PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors

Pharmaessentia Corporation Announces Appointments to Board of Directors

Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee

PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corporation to Report Q1, 2024 Results on May 13, 2024

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia

PharmaEssentia Corporation announced a financing transaction

PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA

PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA

PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China

PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV)

PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi